Keywords: elderly, hypertension, HYVET, older adults, treatment In the pilot study, subjects aged over 80 years, with a sustained blood. Kardiol Pol. Jul;66(7); discussion [HYVET study – treatment for hypertension]. [Article in Polish]. Zalewska J(1). Author information. “In the main HYVET study, we aimed to resolve persistent areas of clinical uncertainty about the relative benefits and risks of antihypertensive.

Author: Goltigrel Zolora
Country: Samoa
Language: English (Spanish)
Genre: Medical
Published (Last): 26 August 2010
Pages: 49
PDF File Size: 20.87 Mb
ePub File Size: 2.51 Mb
ISBN: 145-5-69665-206-3
Downloads: 95818
Price: Free* [*Free Regsitration Required]
Uploader: Nikoran

Reduction in mortality of persons with high blood pressure, including mild hypertension. Support Center Support Center. However there was a non-significant rise in all cause mortality RHR 1.

[HYVET study – treatment for hypertension].

A meta-analysis of RCT data found that treatment of hypertension in this age group was associated with a statistically significant reduction in major CV events and HF but no reduction no CV mortaltiy and an increased risk hyvst all-cause mortality. Received Apr 30; Accepted Aug Some have interpreted HYVET as a negative study, since the P value for the primary outcome of stroke did not reach statistical significance.

Immediate and late benefits of treating very elderly people with hypertension: Introduction The s saw publication of landmark data demonstrating the benefits of anti-hypertensive therapy [ 1 — 3 ].

The role of blood pressure control in preventing complications of hypertension. Despite this, a trend analysis from the EWPHE trial suggested that the treatment of hypertension might be less effective or even harmful to the very old aged over 80 years [ 10 ].

  ISO 20776 PDF

There were also significant reductions in rates of other secondary outcomes including fatal stroke, HF, and CV events. Hypertension — treated and untreated.

The Hypertension in the Very Elderly Trial – latest data

Once again, the relative stury being of the trial participants limits the potential applicability of these data to the general population. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Conflict of interest statement All authors have completed the Unified Competing Interest form at http: Moreover, active treatment was well tolerated.

This appeared to detect small differences between the two trial arms, in favour of treatment.

The trial steering group also published an analysis evaluating the association of depression with cardiovascular mortality and morbidity, all-cause mortality and incident dementia. Additional non-protocol—specified antihypertensives were allowed for up to three months, after which patients were given the option of coming off study or entering open follow-up.

Antihypertensive drugs in very old people: Published online Aug Whilst hyet results strengthen the case for early benefit arising from anti-hypertensive therapy in octogenarians, the selective exclusion criteria are questionable.

The Hypertension in the Very Elderly Trial – latest data

The primary outcome was hyvrt rate of fatal or nonfatal stroke excluding TIA. Thus, the benefit of treatment above 85—90 years of age remains uncertain [ 1819 ]. Sociodemographic and lifestyle risk factors for incident dementia and cognitive decline in the HYVET. Five-year findings of the hypertension Detection and Follow-up Program: More importantly, the early evidence of mortality benefit resulted in a relatively short duration of follow-up median 1.


Association of depression with subsequent mortality, cardiovascular morbidity and incident dementia in people aged 80 and over and suffering from hypertension.

After a 2-month placebo run-in phase, 3, patients were randomized to active treatment or placebo with stratification according to age and sex. JNC 8 hypertension guidelinesstdy [7]. Initially blood pressures were recorded with either a mercury sphygmomanometer or a validated automated device, but at the end of the trial a validated automated device was used in the majority of nyvet [ 13 ].

Thus, social and economic status were not adequately controlled for and reverse causality could not be excluded.

Results of the pilot study for the hypertension in the very elderly trial. Retrieved from ” http: Equally, at the time of the second interim analysis July the relative risk of all stroke fatal and non-fatal amongst those receiving active treatment was 0.

However using these data, a dynamic model of cognition that allowed all outcomes cognitive worsening, stability, improvement or death to be categorized simultaneously was developed.